Vizimpro

Monitor for pulmonary symptoms; withhold and evaluate if worsening symptoms indicative of interstitial lung disease (ILD); permanently discontinue if ILD confirmed. Withhold if Grade 2–4 diarrhea occurs; resume after recovery to Grade ≤1 at same dose or reduced dose based on severity; promptly treat with antidiarrheal. Withhold if persistent Grade 2 or any Grade 3/4 dermatologic adverse reactions occur; resume after recovery to Grade ≤1 at same dose or reduced dose based on reaction severity. Limit sun exposure; initiate moisturizer and appropriate measures at treatment start. If development of Grade 1 rash: treat with topical antibiotics/steroids; if Grade ≥2: treat with oral antibiotics. Severe renal impairment: not established. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥17 days after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥17 days after the last dose).